The staging was done according to the FIGO classification: 14,89% of the patients were stage I, 46,80% stage II, 26,59% stage III and 11,70% of the patients were stage IV. The biopsy results showed that 85,10% of all patients had squamous cell carcinoma, 9,57% adenocarcinoma and 5,31% adenosquamous carcinoma. Multiparity was 86,17% among the cervical cancer patients and only 21,27% of the patients were smokers. 20,21% of the patients had a family history of malignancies. Blood tests were performed and 57,44% of the patients had secondary anaemia and 26,59% had leucopenia. The debut of the cervical cancer consisted in: abnormal bleeding in 85,10% of patients, pelvic pain in 47,87% of patients and 28,72% of women had purulent vaginal discharge. Other debut symptoms include: dyspareunia, abdominal cramps, nausea, frequent urination, etc. 67,03% of patients were treated using surgery, chemotherapy and external beam radiation and in 32,97% of women palliative chemotherapy and external beam radiation were used.